The ketogenic diet in refractory childhood epilepsy.
OBJECTIVE
To report the efficacy and tolerability of the ketogenic diet (KD) in refractory paediatric epilepsy.


METHODS
Twenty-six consecutive children were treated with the classical KD from 1996 to 2001. The epilepsy syndromes included symptomatic generalized epilepsy (15), idiopathic generalized epilepsy (4), symptomatic partial epilepsy (1) and unclassified epilepsy (6). One child was lost to follow up.


RESULTS
Median age at initiation of the KD was 6.1 years. Median duration of the treatment was 9 months. Twelve children (48%) were treated for >12 months; one still remains on the KD. Four children (16%) became seizure-free. Five children (20%) had 50-99% reduction in seizures, seven (28%) had <50% reduction in seizures and eight (36%) had no improvement. Age, seizure-type and aetiology did not predict response. The medications were decreased in 33% of the children. The KD was discontinued in 64% of the children because of poor efficacy and in 12% because of side-effects. Problems during initiation of the KD included asymptomatic hypoglycaemia (24%) and vomiting (12%). Later complications included poor growth (20%), hyperlipidaemia (16%), hypercalcuria (8%), hypocarnitaemia (8%), constipation (8%), pancreatitis (4%) and decreased bone density (4%). There were no deaths. A 3-month trial of the KD costs A3879 dollars. The first 12 months cost A7275 dollars with a cost of A4528 dollars each year, thereafter.


CONCLUSIONS
The KD is an effective treatment for some children with refractory epilepsy, being generally well tolerated and rarely associated with side-effects. Response is not necessarily predicted by age, syndrome or aetiology. A prospective study of the KD is presently underway.
Mackay
Mark T
MT
Children's Epilepsy Program, Department of Neurology, Royal Children's Hospital, University of Melbourne, Melbourne, Victoria, Australia. mark.mackay@rch.org.au
Bicknell-Royle
Jillian
J
Nation
Judy
J
Humphrey
Maureen
M
Harvey
A Simon
AS
D002648:Child; D003365:Costs and Cost Analysis; D004041:Dietary Fats / Q000008:administration & dosage* / Q000009:adverse effects; D004827:Epilepsy / Q000145:classification / Q000178:diet therapy*; D006801:Humans; D007662:Ketosis / Q000139:chemically induced*; D012189:Retrospective Studies; D016896:Treatment Outcome; D014739:Victoria
D004041:Dietary Fats